Wedbush Securities’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $2.36M | Sell |
4,745
-672
| -12% | -$298K | 0.06% | 245 |
|
|
2026
Q1 | $2.42M | Sell |
5,417
-144
| -3% | -$67.1K | 0.07% | 223 |
|
|
2025
Q4 | $2.52M | Sell |
5,561
-589
| -10% | -$254K | 0.07% | 207 |
|
|
2025
Q3 | $2.41M | Sell |
6,150
-472
| -7% | -$197K | 0.08% | 198 |
|
|
2025
Q2 | $2.95M | Buy |
6,622
+19
| +0.3% | +$8.76K | 0.1% | 147 |
|
|
2025
Q1 | $3.2M | Buy |
6,603
+317
| +5% | +$148K | 0.12% | 130 |
|
|
2024
Q4 | $2.53M | Sell |
6,286
-58
| -0.9% | -$26.9K | 0.09% | 161 |
|
|
2024
Q3 | $2.95M | Sell |
6,344
-247
| -4% | -$119K | 0.11% | 137 |
|
|
2024
Q2 | $3.09M | Buy |
6,591
+381
| +6% | +$165K | 0.11% | 136 |
|
|
2024
Q1 | $2.6M | Buy |
6,210
+290
| +5% | +$123K | 0.1% | 157 |
|
|
2023
Q4 | $2.41M | Buy |
5,920
+1,258
| +27% | +$465K | 0.11% | 140 |
|
|
2023
Q3 | $1.62M | Buy |
4,662
+503
| +12% | +$176K | 0.08% | 188 |
|
|
2023
Q2 | $1.46M | Sell |
4,159
-740
| -15% | -$249K | 0.07% | 222 |
|
|
2023
Q1 | $1.54M | Buy |
4,899
+99
| +2% | +$29.7K | 0.08% | 204 |
|
|
2022
Q4 | $1.39M | Buy |
4,800
+127
| +3% | +$38.7K | 0.08% | 220 |
|
|
2022
Q3 | $1.35M | Buy |
4,673
+423
| +10% | +$122K | 0.08% | 211 |
|
|
2022
Q2 | $1.2M | Sell |
4,250
-1,272
| -23% | -$340K | 0.07% | 250 |
|
|
2022
Q1 | $1.44M | Sell |
5,522
-165
| -3% | -$39.2K | 0.07% | 251 |
|
|
2021
Q4 | $1.25M | Sell |
5,687
-2,428
| -30% | -$472K | 0.05% | 299 |
|
|
2021
Q3 | $1.47M | Buy |
8,115
+46
| +0.6% | +$8.98K | 0.07% | 252 |
|
|
2021
Q2 | $1.63M | Buy |
8,069
+1,101
| +16% | +$230K | 0.08% | 235 |
|
|
2021
Q1 | $1.5M | Buy |
6,968
+396
| +6% | +$87K | 0.08% | 223 |
|
|
2020
Q4 | $1.55M | Sell |
6,572
-118
| -2% | -$27.1K | 0.14% | 154 |
|
|
2020
Q3 | $1.82M | Sell |
6,690
-2,697
| -29% | -$744K | 0.17% | 118 |
|
|
2020
Q2 | $2.73M | Buy |
9,387
+149
| +2% | +$40.4K | 0.26% | 80 |
|
|
2020
Q1 | $2.2M | Sell |
9,238
-58
| -0.6% | -$13.3K | 0.26% | 85 |
|
|
2019
Q4 | $2.04M | Sell |
9,296
-30
| -0.3% | -$6.07K | 0.18% | 130 |
|
|
2019
Q3 | $1.58M | Buy |
9,326
+207
| +2% | +$36.6K | 0.15% | 153 |
|
|
2019
Q2 | $1.67M | Sell |
9,119
-97
| -1% | -$17K | 0.17% | 142 |
|
|
2019
Q1 | $1.7M | Sell |
9,216
-208
| -2% | -$38.4K | 0.18% | 122 |
|
|
2018
Q4 | $1.56M | Sell |
9,424
-166
| -2% | -$28.8K | 0.2% | 125 |
|
|
2018
Q3 | $1.85M | Buy |
9,590
+145
| +2% | +$25.8K | 0.21% | 100 |
|
|
2018
Q2 | $1.6M | Sell |
9,445
-977
| -9% | -$151K | 0.2% | 108 |
|
|
2018
Q1 | $1.7M | Buy |
10,422
+215
| +2% | +$35.1K | 0.22% | 105 |
|
|
2017
Q4 | $1.53M | Buy |
10,207
+2,154
| +27% | +$319K | 0.19% | 118 |
|
|
2017
Q3 | $1.22M | Sell |
8,053
-11
| -0.1% | -$1.66K | 0.16% | 136 |
|
|
2017
Q2 | $1.04M | Buy |
+8,064
| New | +$971K | 0.13% | 180 |
|
|
2017
Q1 | – | Sell |
-4,238
| Closed | -$312K | – | 883 |
|
|
2016
Q4 | $312K | Sell |
4,238
-3,456
| -45% | -$281K | 0.05% | 485 |
|
|
2016
Q3 | $671K | Buy |
+7,694
| New | +$727K | 0.1% | 236 |
|
Other funds holding VRTX
Wedbush Securities's VRTX Position: Q2 2026 in Review
Wedbush Securities reduced its Vertex Pharmaceuticals (VRTX) stake by 12% in Q2 2026, selling an estimated $298K and leaving 4,745 shares worth $2.36M. The position accounts for 0.06% of the portfolio, ranked #245.
Wedbush Securities first reported a position in VRTX in Q3 2016 and has held it in 39 quarters since. The position peaked at $3.2M in Q1 2025. 1,747 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.
- Wedbush Securities held 4,745 shares of Vertex Pharmaceuticals worth $2.36M as of Q2 2026.
- Wedbush Securities sold 672 Vertex Pharmaceuticals shares in Q2 2026, an estimated $298K.
- Vertex Pharmaceuticals made up 0.06% of Wedbush Securities's portfolio in Q2 2026, its #245 holding.
- Wedbush Securities first reported a position in Vertex Pharmaceuticals in Q3 2016 and has held it in 39 quarters since.
- Wedbush Securities's Vertex Pharmaceuticals position peaked at $3.2M in Q1 2025.
- 1,747 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.
Based on Wedbush Securities's 13F filing for Q2 2026, filed 28 Jul 2026.